Dianthus Therapeutics Quarterly Cash Flow Statement
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
82.37-0.06 (-0.07%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dianthus Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Dianthus Therapeutics generated -$49.0 million of operating cash flow and spent $181,000 on capital expenditures. That left free cash flow of -$49.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Dianthus Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -50.22M | -40.83M | -64.43M | -36.77M | -31.63M | -29.51M | -28.44M | -25.17M | -17.61M | -13.75M | -10.56M | -14.76M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -167.53% |
| Depreciation & Amortization | 37.00K | 32.00K | 27.00K | 27.00K | 30.00K | 27.00K | 26.00K | 25.00K | 23.00K | 22.00K | 20.00K | 19.00K |
| Stock-Based Compensation | 11.90M | 10.60M | 5.98M | 5.79M | 5.71M | 5.32M | 3.92M | 3.84M | 3.10M | 2.04M | 726.00K | 1.18M |
| Change in Working Capital | 1.97M | -2.45M | 4.68M | -114.00K | -629.00K | 943.00K | -2.67M | -1.62M | -1.83M | 343.00K | -991.00K | -20.00K |
| Operating Cash Flow | -48.98M | -28.86M | -46.98M | -30.55M | -23.89M | -27.63M | -27.44M | -21.27M | -14.53M | -14.94M | -11.85M | -9.99M |
| Capital Expenditures | -181.00K | -10.00K | -138.00K | -5.00K | -46.00K | -24.00K | -31.00K | -25.00K | -17.00K | -32.00K | -10.00K | -65.00K |
| Investing Cash Flow | -478.52M | -133.97M | 37.20M | -201.28M | 26.45M | 14.79M | -23.11M | -259.36M | 1.17M | -5.51M | -8.24M | -11.51M |
| Financing Cash Flow | 10.38M | 739.41M | 4.88M | 274.51M | 568.00K | 161.00K | 39.68M | 296.00K | -2.20M | 217.85M | -4.87M | 138.44M |
| Net Change in Cash | -517.12M | 576.58M | -4.90M | 42.68M | 3.12M | -12.68M | -10.88M | -280.33M | -15.55M | 197.40M | -24.96M | 116.94M |
| Free Cash Flow | -49.16M | -28.87M | -47.12M | -30.56M | -23.94M | -27.65M | -27.48M | -21.29M | -14.54M | -14.97M | -11.86M | -10.06M |
This table shows 12 quarterly periods of Dianthus Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DNTH's reporting calendar. What is a cash flow statement?